Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating restated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Friday. They currently have a $135.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 69.32% from the stock’s current price.
The analysts wrote, “. We reiterate our Overweight rating and 12-mo. $135 PT. Alnylam hosted an R&D day Thursday, where pipeline updates and long-term strategy were largely in line with our recently published expectations here. With three Ph3 readouts and two potential NDA filings in 2019 alone, we think ALNY is well on its way to establishing itself as a diversified global commercial biotech company, if pipeline execution continues. We see many late and mid-stage readouts over the next 12 months that will help ALNY build more commercial and mid/late- stage products (see p. 2). ALNY will preannounce 4Q18 Onpattro sales in early Jan. 2019.””
ALNY has been the subject of a number of other research reports. Leerink Swann began coverage on Alnylam Pharmaceuticals in a report on Tuesday, November 27th. They set a “market perform” rating and a $63.00 target price for the company. BidaskClub cut Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 10th. BMO Capital Markets reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, October 18th. Zacks Investment Research cut Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, October 8th. Finally, Morgan Stanley reduced their target price on Alnylam Pharmaceuticals from $93.00 to $87.00 and set an “equal weight” rating for the company in a report on Friday, September 28th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $138.44.
NASDAQ ALNY opened at $79.73 on Friday. The stock has a market capitalization of $7.92 billion, a P/E ratio of -14.71 and a beta of 2.54. Alnylam Pharmaceuticals has a twelve month low of $63.57 and a twelve month high of $153.99. The company has a quick ratio of 10.96, a current ratio of 11.05 and a debt-to-equity ratio of 0.02.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($0.41). The business had revenue of $2.07 million during the quarter, compared to analyst estimates of $22.66 million. Alnylam Pharmaceuticals had a negative return on equity of 43.07% and a negative net margin of 754.13%. The business’s revenue for the quarter was down 87.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.34) EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals will post -7.75 EPS for the current year.
Hedge funds have recently bought and sold shares of the company. Riverhead Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 195.6% in the second quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock valued at $233,000 after purchasing an additional 1,565 shares in the last quarter. Advisors Asset Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 269.8% in the 2nd quarter. Advisors Asset Management Inc. now owns 54,368 shares of the biopharmaceutical company’s stock valued at $1,674,000 after purchasing an additional 39,665 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $398,000. Northern Trust Corp boosted its holdings in Alnylam Pharmaceuticals by 4.4% in the 2nd quarter. Northern Trust Corp now owns 492,768 shares of the biopharmaceutical company’s stock valued at $48,533,000 after purchasing an additional 20,992 shares in the last quarter. Finally, Fosun International Ltd purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $3,288,000. Institutional investors and hedge funds own 88.46% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Recommended Story: How Investors Use a Balance Sheet
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.